文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

简约算法用于急性呼吸窘迫综合征表型分类的开发与验证:随机对照试验的二次分析

Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials.
PubMed 文献 · Lancet Respir Med · 2020-01-13
一句话结论用IL-8、碳酸氢盐、蛋白C(加或不加升压药使用)三个或四个变量构建的简约模型可准确识别ARDS高炎症与低炎症表型,尚待实时生物标志物检测与前瞻性验证。

本研究为回顾性二次分析,用美国国家肺、心、血液研究所ARDS网络三个随机对照试验队列(ARMA、ALVEOLI、FACTT,n=2022)作为推导集,以潜在类别分析(LCA)表型为参考标准,用机器学习筛选最多6个分类变量并构建嵌套逻辑回归模型;第四个队列(SAILS,n=715)作为验证集。最重要的6个变量为IL-8、IL-6、蛋白C、可溶性肿瘤坏死因子受体1、碳酸氢盐和升压药使用;三变量模型(IL-8、碳酸氢盐、蛋白C)与四变量模型(加升压药使用)表现最佳,验证集AUC分别为0.94(95%CI 0.92-0.95)和0.95(95%CI 0.93-0.96)。分类模型识别的高炎症表型90天死亡率更高(223例中87例[39%] vs 492例中112例[23%],p<0.0001),无呼吸机天数更少(中位14天[IQR 0-22] vs 22天[0-25],p<0.0001)。外部验证集(START和HARP-2)中三变量模型识别出临床特征与结局不同的两种表型,与既往发现一致,包括HARP-2中辛伐他汀与安慰剂生存差异(28天生存p=0.023)。作者认为,在关键生物标志物实时检测与前瞻性验证完成前,这些模型可促进ARDS表型识别以用于临床试验和实践。

要点

  • 三变量模型(IL-8、碳酸氢盐、蛋白C)与四变量模型(加升压药使用)在验证集中对LCA表型的AUC分别为0.94(95%CI 0.92-0.95)和0.95(95%CI 0.93-0.96)。
  • 分类模型识别的高炎症表型90天死亡率更高:223例中87例(39%)vs 492例中112例(23%),p<0.0001。
  • 高炎症表型无呼吸机天数更少:中位14天(IQR 0-22)vs 22天(IQR 0-25),p<0.0001。
  • 外部验证集HARP-2中,推导集三变量模型识别出的表型显示辛伐他汀与安慰剂28天生存差异,p=0.023。
  • 作者认为,在关键生物标志物实时检测与前瞻性验证之前,这些模型可促进ARDS表型识别以用于临床试验和实践。

适用人群与场景

  • 推导集为美国国家肺、心、血液研究所ARDS网络三个随机对照试验队列(ARMA、ALVEOLI、FACTT,n=2022)中的ARDS患者,变量选择仅用推导集中生物标志物数据完整的病例。
  • 验证集为同一网络第四个随机对照试验队列(SAILS,n=715)中的ARDS患者。
  • 外部验证为两个ARDS临床试验数据集(START和HARP-2)。

诊断标准与关键阈值

  • 以潜在类别分析(LCA)推导的表型作为参考标准。
  • 三变量分类模型使用IL-8、碳酸氢盐和蛋白C;四变量模型为三变量加升压药使用。

研究设计与关键结果

  • 研究类型为回顾性二次分析,推导集n=2022,验证集n=715,外部验证集为START和HARP-2。
  • 机器学习筛选出的6个最重要分类变量为IL-8、IL-6、蛋白C、可溶性肿瘤坏死因子受体1、碳酸氢盐和升压药使用。
  • 三变量与四变量模型被判定为表现最佳;验证集AUC三变量模型0.94(95%CI 0.92-0.95),四变量模型0.95(95%CI 0.93-0.96)。
  • 分类模型识别的高炎症表型90天死亡率更高(223例中87例[39%] vs 492例中112例[23%],p<0.0001),无呼吸机天数更少(中位14天[IQR 0-22] vs 22天[IQR 0-25],p<0.0001)。
  • 外部验证集中,推导集开发的三变量模型识别出两种临床特征与结局不同的表型,与既往发现一致,包括HARP-2中辛伐他汀与安慰剂28天生存差异(p=0.023)。

证据类型、等级与局限

  • 证据类型:随机对照试验的回顾性二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在关键生物标志物实时检测与前瞻性验证完成前,这些模型可促进ARDS表型识别以用于临床试验和实践。
  • 原文未据此给出具体床旁治疗推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Using latent class analysis (LCA) in five randomised controlled trial (RCT) cohorts, two distinct phenotypes of acute respiratory distress syndrome (ARDS) have been identified: hypoinflammatory and hyperinflammatory. The phenotypes are associated with differential outcomes and treatment response. The objective of this study was to develop parsimonious models for phenotype identification that could be accurate and feasible to use in the clinical setting.

METHODS: In this retrospective study, three RCT cohorts from the National Lung, Heart, and Blood Institute ARDS Network (ARMA, ALVEOLI, and FACTT) were used as the derivation dataset (n=2022), from which the machine learning and logistic regression classifer models were derived, and a fourth (SAILS; n=715) from the same network was used as the validation test set. LCA-derived phenotypes in all of these cohorts served as the reference standard. Machine-learning algorithms (random forest, bootstrapped aggregating, and least absolute shrinkage and selection operator) were used to select a maximum of six important classifier variables, which were then used to develop nested logistic regression models. Only cases with complete biomarker data in the derivation dataset were used for variable selection. The best logistic regression models based on parsimony and predictive accuracy were then evaluated in the validation test set. Finally, the models' prognostic validity was tested in two external ARDS clinical trial datasets (START and HARP-2) by assessing mortality at days 28, 60, and 90 and ventilator-free days to day 28.

FINDINGS: The six most important classifier variables were interleukin (IL)-8, IL-6, protein C, soluble tumour necrosis factor receptor 1, bicarbonate, and vasopressor use. From the nested models, three-variable (IL-8, bicarbonate, and protein C) and four-variable (3-variable plus vasopressor use) models were adjudicated to be the best performing. In the validation test set, both models showed good accuracy (AUC 0·94 [95% CI 0·92-0·95] for the three-variable model and 0·95 [95% CI 0·93-0·96] for the four-variable model) against LCA classifications. As with LCA-derived phenotypes, the hyperinflammatory phenotype as identified by the classifier model was associated with higher mortality at day 90 (87 [39%] of 223 patients vs 112 [23%] of 492 patients; p<0·0001) and fewer ventilator-free days (median 14 days [IQR 0-22] vs 22 days [0-25]; p<0·0001). In the external validation datasets, three-variable models developed in the derivation dataset identified two phenotypes with distinct clinical features and outcomes consistent with previous findings, including differential survival with simvastatin versus placebo in HARP-2 (p=0·023 for survival at 28 days).

INTERPRETATION: ARDS phenotypes can be accurately identified with parsimonious classifier models using three or four variables. Pending the development of real-time testing for key biomarkers and prospective validation, these models could facilitate identification of ARDS phenotypes to enable their application in clinical trials and practice.

FUNDING: National Institutes of Health.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Sinha P, Delucchi KL, McAuley DF, et al. Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials. Lancet Respir Med. 2020. PMID: 31948926. doi:10.1016/S2213-2600(19)30369-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。